Australia's most trusted
source of pharma news
Posted 25 May 2022 PM
Melbourne-based clinical stage cell therapy company Chimeric Therapeutics has exercised an exclusive option with a US university for a new platform technology that can develop next-generation, off-the-shelf Natural Killer (NK) and CAR NK products.
NK cells have innate safety features and the natural ability to target and destroy cancer cells through both indirect and direct mechanisms.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.